Brown Advisory Inc. increased its stake in shares of Masimo Co. (NASDAQ:MASI) by 10.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,243 shares of the medical equipment provider’s stock after buying an additional 2,418 shares during the quarter. Brown Advisory Inc.’s holdings in Masimo were worth $2,464,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of MASI. Mount Yale Investment Advisors LLC bought a new stake in Masimo during the first quarter worth $101,000. Cerebellum GP LLC bought a new stake in Masimo during the second quarter worth $173,000. US Bancorp DE lifted its stake in Masimo by 36.9% during the second quarter. US Bancorp DE now owns 1,980 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 534 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Masimo during the first quarter worth $202,000. Finally, Matisse Capital bought a new stake in Masimo during the second quarter worth $202,000. 83.88% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Joe E. Kiani sold 126,927 shares of the stock in a transaction on Friday, August 31st. The stock was sold at an average price of $117.85, for a total value of $14,958,346.95. Following the completion of the transaction, the chief executive officer now directly owns 236,061 shares in the company, valued at approximately $27,819,788.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sanford Fitch sold 2,000 shares of the stock in a transaction on Friday, July 6th. The shares were sold at an average price of $100.00, for a total value of $200,000.00. Following the completion of the transaction, the director now owns 59,832 shares of the company’s stock, valued at $5,983,200. The disclosure for this sale can be found here. Insiders sold a total of 472,200 shares of company stock valued at $54,742,687 over the last quarter. 12.60% of the stock is owned by corporate insiders.
Several research firms have weighed in on MASI. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 17th. ValuEngine cut Masimo from a “buy” rating to a “hold” rating in a research note on Thursday, June 7th. Stifel Nicolaus upped their target price on Masimo from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Zacks Investment Research cut Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, August 1st. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Masimo presently has a consensus rating of “Buy” and an average price target of $102.60.
NASDAQ MASI opened at $118.92 on Friday. Masimo Co. has a fifty-two week low of $80.69 and a fifty-two week high of $120.45. The firm has a market cap of $6.10 billion, a price-to-earnings ratio of 48.15, a price-to-earnings-growth ratio of 2.75 and a beta of 1.02.
Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.02. Masimo had a return on equity of 21.49% and a net margin of 15.30%. The company had revenue of $211.62 million during the quarter, compared to analysts’ expectations of $207.85 million. During the same period in the prior year, the company earned $0.83 EPS. Masimo’s revenue was up 10.0% compared to the same quarter last year. equities analysts anticipate that Masimo Co. will post 2.9 EPS for the current fiscal year.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.